mTORC1型
癌症研究
生物
克隆形成试验
髓样
脱甲基酶
基因敲除
细胞培养
细胞生物学
基因
组蛋白
信号转导
PI3K/AKT/mTOR通路
遗传学
作者
Gauri Deb,Bettina Wingelhofer,Fabio M. R. Amaral,Alba Maiqués-Díaz,John Chadwick,Gary J. Spencer,Emma L. Williams,Hui Sun Leong,Tamara Maes,Tim C. P. Somervaille
出处
期刊:Leukemia
[Springer Nature]
日期:2019-11-28
卷期号:34 (5): 1266-1277
被引量:36
标识
DOI:10.1038/s41375-019-0659-6
摘要
Abstract The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the MLL -translocated molecular subtype of AML. In AML, the use of drugs in combination often delivers superior clinical activity. To identify genes and cellular pathways that collaborate with LSD1 to maintain the leukaemic phenotype, and which could be targeted by combination therapies, we performed a genome-wide CRISPR-Cas9 dropout screen. We identified multiple components of the amino acid sensing arm of mTORC1 signalling—RRAGA, MLST8, WDR24 and LAMTOR2—as cellular sensitizers to LSD1 inhibition. Knockdown of mTORC1 components, or mTORC1 pharmacologic inhibition, in combination with LSD1 inhibition enhanced differentiation in both cell line and primary cell settings, in vitro and in vivo, and substantially reduced the frequency of clonogenic primary human AML cells in a modelled minimal residual disease setting. Synergistic upregulation of a set of transcription factor genes associated with terminal monocytic lineage differentiation was observed. Thus, dual mTORC1 and LSD1 inhibition represents a candidate combination approach for enhanced differentiation in MLL -translocated AML which could be evaluated in early phase clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI